jean-pierre Bizzari

From 2002 to 2008, he was the Vice President of Clinical Development, Oncology at Sanofi-Aventis, and from 2008 to 2016 was Executive Vice-President, Group Head, Clinical Oncology Development (U.S., Europe, and Asia / Japan) at Celgene.

Dr. Bizzari is also an active board member of various biotech companies, such as Transgene in France, Compugen in Israel, and Halozyme Therapeutics and Oxford BioTherapeutics in the US.

Jean-Pierre is currently President / Director of the Synergie Lyon Cancer Foundation, and a scientific member of the French National Cancer Institute. He has supervised the clinical development and global approval of oncological agents that have been at the forefront of modern anti-cancer therapies, including Taxotere, Abraxane, Eloxatin, Irinotecan, as well as numerous anti-angiogenic (VEGF-trap) gene therapies, vaccines, and bio-reductive agents. At Celgene, his oversight and expansion of the IMiD programme, developing therapies such as Revlimid, had a globally transformative impact on the treatment of Multiple Myeloma patients.

He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses and is a sought-after global authority on the development of modern pharmaceutical therapies.